Cited by 673Heart Failure Treatment and ManagementHeart rate and cardiovascular healthRenin-Angiotensin System Studies

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

Open access
Packer, Milton, McMurray, John J.V., Desai, Akshay S., Gong, Jianjian, Lefkowitz, Martin P., Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C. +44 more·2015·Circulation

Abstract

Background—: Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. Methods and Results—: We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of medical treatment for heart failure (520 versus 604; hazard ratio, 0.84; 95% confidence interval, 0.74–0.94; P =0.003) or an emergency department visit for worsening heart failure (hazard ratio, 0.66; 95% confidence interval, 0.52–0.85; P =0.001). The patients in the LCZ696 group had 23% fewer hospitalizations for worsening heart failure (851 versus 1079; P <0.001) and were less likely to require intensive care (768 versus 879; 18% rate reduction, P =0.005), to receive intravenous positive inotropic agents (31% risk reduction, P <0.001), and to have implantation of a heart failure device or cardiac transplantation (22% risk reduction, P =0.07). The reduction in heart failure hospitalization with LCZ696 was evident within the first 30 days after randomization. Worsening of symptom scores in surviving patients was consistently more common in the enalapril group. LCZ696 led to an early and sustained reduction in biomarkers of myocardial wall stress and injury (N-terminal pro–B-type natriuretic peptide and troponin) versus enalapril. Conclusions—: Angiotensin-neprilysin inhibition prevents the clinical progression of surviving patients with heart failure more effectively than angiotensin-converting enzyme inhibition. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01035255.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.114.013748

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Lawless JF, Nadeau JC. Nonparametric estimation of cumulative mean functions for recurrent events. Technometrics. 1995;37:158-168.
  2. Wei LJ, Glidden DV. An overview of statistical methods for multiple fail- ure time data in clinical trials. Stat Med. 1997;16:833-839.

Cited by

Sorted by citations

Authors
Packer, M., McMurray, J. J. V., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., Zile, M., Andersen, K., Arango, J. L., Arnold, J. M., Bělohlávek, J., Böhm, M., Boytsov, S., Burgess, L. J., Cabrera, W., Calvo, C., Chen, C.-H., Dukat, A., Duarte, Y. C., Erglis, A., Fu, M., Gomez, E., Gonzàlez-Medina, A., Hagège, A. A., Huang, J., Katova, T., Kiatchoosakun, S., Kim, K.-S., Kozan, Ö., Llamas, E. B., Martinez, F., Merkely, B., Mendoza, I., Mosterd, A., Negrusz-Kawecka, M., Peuhkurinen, K., Ramires, F. J. A., Refsgaard, J., Rosenthal, A., Senni, M., Sibulo, A. S., Silva-Cardoso, J., Squire, I. B., Starling, R. C., Teerlink, J. R., Vanhaecke, J., Vinereanu, D., & Wong, R. C.-C.
Affiliations
  • Brigham and Women's Hospital (US)
  • From the Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX (M.P.); BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK (J.J.V.M.); Brigham and Women’s Hospital, Cardiovascular Medicine, MA (A.S.D., S.D.S.); Novartis Pharmaceutical Corporation, East Hanover, NJ (J.G., M.P.L., A.R.R., V.C.S.); Université de Montréal, Institut de Cardiologie, Montréal, Canada (J.L.R.); Department of Molecular and Clinical Medicine, Gothenburg,...
Venue
Circulation
Published
2015-01-06
Volume
131
Issue
1
Pages
54-61
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2097123331
Cited by
673
References
47
Citations by year
2026: 17 · 2025: 30 · 2024: 29 · 2023: 52 · 2022: 40 · 2021: 54 · 2020: 51 · 2019: 72 · 2018: 78 · 2017: 91 · 2016: 101 · 2015: 55 · 2014: 2
FWCI
56.92
Type
journal article
Language
en
Open access
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
  • SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
  • Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
  • Research Bank (Australian Catholic University) (submittedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
  • RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
  • Hirsla (Landspítali University Hospital) (submittedVersion)
Funders
Medical Research Council (MR/K006665/1, MC_PC_13042)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Keywords
sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, clinical deterioration, heart failure hospitalization, emergency department visits, intensive care, positive inotropic agents, N-terminal pro-brain natriuretic peptide, troponin, symptom worsening, ACE inhibitors
MeSH terms
Valsartan, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Double-Blind Method, Drug Combinations, Enalapril, Heart Failure, Humans, Peptide Fragments, Risk Factors, Stroke Volume, Tetrazoles, Troponin, Neprilysin, Biomarkers, Treatment Outcome, Survivors, Disease Progression, Natriuretic Peptide, Brain, Kaplan-Meier Estimate, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review